Insmed
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
700 Us Highway 202/206, Bridgewater, New...Phone Number
(908) 977-9900Website
www.insmed.comRevenue
$819.6 MillionStock Symbol
INSMIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
7
1
2
2
2
1
About Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.Explore more
Insmed Org Chart
MF
Senior Vice President Commercial Head of Gene...
SB
Senior Vice President & General Manager, Glob...
IF
Head Senior VP, Medical Affairs
KC
Vice President, Field Medical (US)
JZ
Vice President, Head of Toxicology and Molecu...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Insmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Insmed has new funding data
Click to see if Insmed had a recent Job posting/layoffs
Insmed, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Insmed has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Insmed launches new products
Website visits: Recent activity has been detected on your website
Check out if Insmed is spiking on competitors!
Earning: See what the market has to say on Insmed recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Insmed
Recommended Actions
Reach out to Masked Content who joined Insmed as Masked Content
Find more new buyers
Compare Similar Companies to Insmed
Compare insights from companies similar to Insmed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Insmed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Insmed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Insmed.
Insmed financials insights
Gather financial insights about Insmed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$775M
Insmed Tech Stack
A closer look at the technologies used by Insmed
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Person-Based
Medical Research
Insmed News & Media
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by...Mizuho Maintains an Outperform Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the Best Healthcare Stocks. On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ:INSM) to $192 from $202. It maintained an Outperform rating on the shares. The firm stated the recent selloff created a buying opportunity even though shares have fallen 29% since the company’s first-quarter report. Mizuho found […]EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Insmed
Sign Up For FreeTo access detailed company insights
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients... Read More
